ulcerative colitis

Sanofi shows how $500M IBD bet compares to Merck, Roche rivals

Sanofi shared a deeper dive into phase 2 data, providing a clearer look at how the Teva-partnered prospect compares to Merck and Roche’s rival assets.

Nick Paul Taylor Feb 24, 2025 8:11am

Odyssey, Sionna join band of biotechs braving the IPO waters

Jan 21, 2025 5:27am

Sanofi, Teva tout midstage win for TL1A antibody in Crohn’s, UC

Dec 17, 2024 10:30am

OSE's ulcerative colitis prospect improves symptoms in phase 2

Jul 24, 2024 8:23am

Photo of a final puzzle piece about to fit into a puzzle

Lilly inks $3.2B Morphic buyout to take on Takeda in IBD

Jul 8, 2024 8:20am

Palisade's ulcerative colitis drug prevents symptoms in mice

May 23, 2024 4:30am